THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses.
The equity offering is comprised of 1,376,287 common stock units (or pre-funded warrant units in lieu of common stock units), priced at a public offering price of $6.54 per common stock unit (or $6.539 per pre-funded warrant unit). Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.001) and one warrant to purchase one share of common stock that expires on the five-year anniversary of the date of issuance (a “Series A Warrant”). The exercise price for the Series A warrant is $6.54 per share. The warrants to be issued in this transaction are fixed priced and do not contain any variable pricing features. The securities comprising the units are immediately separable and will be issued separately.
In addition, the Company has granted the underwriter a 45-day option to purchase additional shares of common stock and/or Series A warrants, representing up to 15% of the number of securities sold in the offering, solely to cover over-allotments, if any.
Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering.
The offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company intends to use the net proceeds from this offering to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
